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Abstract The concept that a specific alteration in an
individual’s DNA can result in disease is central to our
notion of molecular medicine. The molecular basis of more
than 3,500 Mendelian disorders has now been identified. In
contrast, the identification of genes for common disease has
been much more challenging. We discuss historical and
contemporary approaches to disease gene identification,
focusing on novel opportunities such as the use of popu-
lation extremes and the identification of rare variants.
While our ability to sequence DNA has advanced dra-
matically, assigning function to a given sequence change
remains a major challenge, highlighting the need for both
bioinformatics and functional approaches to appropriately
interpret these data. We review progress in mapping and
identifying human disease genes and discuss future chal-
lenges and opportunities for the field.
Introduction
A principal aim of medical genetics is the identification
of the specific genes that, when altered, result in human
disease. Most of the success in this endeavor has
occurred in the context of Mendelian disorders—genetic
diseases thought to reflect the action of a single gene-
product with major effect. This group of disorders are
recognizable in families by their adherence to one of the
canonical patterns of inheritance first described by Gre-
gor Mendel in 1865 and re-discovered in the early
1900s: autosomal recessive, autosomal dominant, co-
dominant or sex-linked. Mendelian disorders are indi-
vidually rare and affect less than 5 % of the population
but are extraordinarily numerous. More than 7,000 such
disorders have been described (Online Mendelian Inher-
itance in Man 2012), and countless other ‘‘private syn-
dromes’’ may exist in only small numbers of individuals
or even single families.
More than 3,600 Mendelian disorders, or *50 % of all
those described, have now been associated with a specific
molecular defect (Online Mendelian Inheritance in Man
2012) (Fig. 1), speaking to both the remarkable success
and the ongoing opportunity that exists in human dis-
ease gene mapping. Pathogenic mutations have been
described in slightly more than 5,000 human genes (Human
Gene Mutation Database. http://www.hgmd.cf.ac.uk/ac/
hahaha.php). However, data from other organisms suggest
that a much higher percentage of the*22,000 human genes
may be associated with phenotypes when altered. For
example, systematic gene mutation screens in yeast and mice
suggest that most of the genes in those organisms are non-
lethal and associated with a discernible phenotype when
disrupted (Ayadi et al. 2012; Winzeler et al. 1999; Hillen-
meyer et al. 2008).
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Mapping genes by positional cloning
For most of the modern era of human genetics, the prin-
cipal method for the identification of disease-associated
genes was positional cloning using linkage analysis. In this
methodology, one or more pedigrees in which the trait of
interest is observed to segregate are used for study. DNA
from both affected and unaffected individuals are geno-
typed for polymorphic markers spread throughout the
genome. Making use of the recombination that occurs in
meiosis, one can then identify a chromosomal region that,
based on the presumed mode of inheritance, shows segre-
gation of a disease-associated haplotype in affected indi-
viduals, and of a non-disease-associated haplotype in
unaffected individuals.
Linkage analysis was first described in fruit flies
100 years ago (Sturtevant 1913) but it was not until the
discovery of naturally occurring polymorphic DNA mark-
ers in the 1980s that this tool first became available to map
human disease genes (Botstein et al. 1980). One of the
early successes was mapping of the gene for Huntington
disease in 1983 (Gusella et al. 1983). Other examples that
soon followed included the genes for cystic fibrosis
(Rommens et al. 1989; Knowlton et al. 1985; White et al.
1985), Duchenne muscular dystrophy (Koenig et al. 1987)
and many others.
To proceed from an area of linkage to a disease-asso-
ciated mutation requires knowledge of the specific genes
that exist in that chromosomal region. In the pre-human
genome era, this involved examination of additional
recombinant chromosomes to further refine the linkage
interval and a variety of molecular biology techniques to
identify expressed genes in the region and search for
mutations. The Herculean nature of this task is demon-
strated by the fact that it took international research groups
a decade to go from identifying the Huntington disease
locus to cloning the disease gene and identifying patho-
genic mutations, in that case a triplet expansion in the HTT
gene (MacDonald et al. 1993). With the completion of the
initial sequencing of the human genome (Lander et al.
2001; Venter et al. 2001), this task has been tremendously
facilitated with a corresponding acceleration in the identi-
fication of Mendelian disease genes (Fig. 1). From the
1980s to the year 2000, the molecular basis of approxi-
mately 1,000 Mendelian disorders had been discovered. In
the first 10 years following the publication of the human
genome, this number more than tripled to over 3,000,
representing one of the indisputable fruits of the Human
Genome Project with direct impact to the patients affected
by these disorders and their families.
A form of linkage analysis that can be used in consan-
guineous families with suspected autosomal recessive traits
is homozygosity mapping. This makes use of the principle
that DNA markers in the chromosomal region immediately
adjacent to the disease locus should be homozygous by
descent in such cases (Lander and Botstein 1987). This
strategy can efficiently identify genomic regions in which
candidate genes can then be tested for the presence of
pathogenic mutations. Homozygosity mapping has recently
been used in combination with high-density whole genome
genotyping to identify disease genes in patients in whom
homozygosity by descent is suspected (Molho-Pessach
et al. 2012).
The biological and medical importance of these disease-
gene discoveries cannot be overstated. Once a disease gene
for a Mendelian disorder is identified, an enormous amount
of information about the biological function of that gene is
provided by the phenotype of individuals in whom it is
dysfunctional. Conversely, study of the biological path-
ways that the gene-product is involved in illuminates dis-
ease pathophysiology. From a clinical perspective,
identification of a disease gene opens the door to diagnostic
and predictive testing where appropriate. For instance,
predictive testing for Huntington disease became available
in Canada in 1987 using linkage analysis based on locali-
zation of the Huntington disease gene (Fox et al. 1989).
Moreover, mutation identification can directly lead to
therapeutic insight and already significant advances in
targeted therapies have been achieved by understanding



































































Fig. 1 Mendelian diseases of known molecular basis. The x-axis
shows the time in years from 1988 to present. The left-hand y-axis
indicates the cumulative number of Mendelian diseases for which a
molecular basis is identified and the right-hand y-axis expresses this
as a percentage of the approximately 7,000 Mendelian disorders that
have been described. The first disease Mendelian disease gene to be
cloned was the CFTR transporter involved in cystic fibrosis in 1989.
Following the release of the first draft of the human genome sequence
in 2001, the rate of discovery of Mendelian disease genes increased
dramatically. As of November 2012, the molecular basis of 3,650
Mendelian diseases, or slightly more than 50 % of all Mendelian
diseases, is known. Data are adapted from (McKusick 2007;
Antonarakis and Beckmann 2006; Hamosh et al. 2005; Pearson
et al. 1994; Online Mendelian Inheritance in Man 2012)
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genotype. For instance, cystic fibrosis (CF) is caused by a
variety of different mutations in the chloride transporter
encoded by the CFTR gene. Some mutations, such as the
common DF508 mutation, result in inability of the encoded
protein to reach the plasma membrane. Other mutations,
such as G551D which is present in *5 % of patients, are
associated with transport of the protein to the cell surface
but failure of the channel to open. Ivacaftor is a novel small
molecule that potentiates the CFTR channel at the cell
surface (Eckford et al. 2012) and leads to significant
improvements in lung-function in patients with the G551D
mutation (Ramsey et al. 2011). In January 2012, this drug
was approved by the Food and Drug Administration for
treatment of CF in patients who carry this mutation,
making this the first genotype-specific therapy for CF.
A second example involves lipoprotein lipase defi-
ciency, a condition characterized by extremely high levels
of triglycerides in plasma and recurrent attacks of painful
pancreatitis. Identification of the LPL S447X mutation and
understanding of its biochemical phenotype as a gain-of-
function variant (Ross et al. 2005) ultimately led to the
development of the first approved gene therapy product for
humans (Yla-Herttuala 2012). Both of these examples
illustrate how the understanding of genotype can lead to
profound clinical insight, both by guiding appropriate
patient selection and by directly leading to the development
of new therapeutic products.
Role of next-generation sequencing in disease gene
identification
The development of massively paralleled (next generation)
sequencing has lead to dramatic acceleration in the pace of
genetic discovery. These technologies have enabled two
major advances of relevance to the discovery of disease-
associated genes. The first is the ability to readily sequence
the genome of a single person, thus allowing identification
of mutations specific to that individual (previous ‘‘human
genomes’’ represented consensus sequences of DNA from
several individuals and were, therefore, not suited to the
identification of rare mutations). The second major appli-
cation of next-generation sequencing is the ability to per-
form whole exome sequencing (WES) in which a targeted
capture strategy is used to sub-select the protein-coding
exonic portion of the genome and generate sequence data
of all known genes (Teer and Mullikin 2010). This results
in sequence data covering *30 MB of the genome, or
*1 % of that examined by whole genome sequencing
(WGS), enabling the identification of mutations that result
in changes to the amino-acid sequence of encoded proteins
while substantially reducing the computational require-
ments associated with analyzing the resulting data.
Examining only the exonic portion of the genome is jus-
tified on the basis that the vast majority of Mendelian
disease-associated mutations identified by positional clon-
ing strategies result in disruption of the protein-coding
sequence (Stenson et al. 2009).
Sequencing of human exomes was first reported in 2009
(Ng et al. 2009) and the use of this technology to discover
the genetic cause of a Mendelian disorder, Miller syn-
drome, followed soon after (Ng et al. 2010). Importantly,
this demonstrated that WES makes tractable those condi-
tions that are too rare and in which appropriately sized
families are not available for positional cloning strategies,
illustrating the power of this approach in situations where
only small numbers of affected individuals are available for
study.
WES and WGS strategies have now been used to elu-
cidate the molecular etiology of an ever-expanding list of
Mendelian disorders, as reviewed elsewhere (Gonzaga-
Jauregui et al. 2012; Ku et al. 2011; Bamshad et al. 2011).
While this undoubtedly represents a major advance for
mapping human disease genes, several challenges remain.
Capture methods remain imperfect and can result in
unequal depth of coverage at different exonic regions. Our
incomplete annotation of all human genes results in a
necessarily incomplete view of the human exome. The
analytical challenges are also significant. Each sequenced
exome results in 20,000–25,000 variants relative to the
reference sequence (Bamshad et al. 2011). How do we go
from this huge number of variants to a single pathogenic
mutation? Typically a number of filtering steps are
employed (Bamshad et al. 2011), for instance, by ruling out
any variants found in public databases such as dbSNP,
1000 Genomes Project, HapMap or locally available
exome databases (Stitziel et al. 2011). This rests on the
assumption that the causative variant will be extremely rare
and that any individual with the variant will be affected
(i.e., the variant is fully penetrant). While this is an effi-
cient method to rule out the vast majority of variants, and is
reasonable in scenarios where the disease-causing variant
is hypothesized to be novel, it may be overly restrictive. As
more genome and exome sequences are deposited in public
repositories, the assumption that any variant found in these
databases can be ruled out as disease-causing becomes
increasingly difficult to justify. This is especially the case
for recessive conditions in which the carrier state is rela-
tively common (e.g., HFE gene mutations associated with
hereditary hemochromatosis) or in situations in which the
causative mutation is not fully penetrant. As a result, many
groups now set frequency-based tolerances for variants
found in dbSNP or other databases, such that variants
present in fewer than 1 % of chromosomes are carried
forward as candidates for a rare pathogenic mutation
(McDonald et al. 2012).
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An additional method to reduce the complexity of ex-
ome sequence data is through integration with family data
or with traditional linkage analysis. For example, if two
affected first cousins are used, the number of variants to be
considered as candidates is reduced to the roughly 1/8th of
the genome shared by two such individuals (Fig. 2). Sim-
ilarly, the use of two affected second cousins reduces the
number of shared variants to 1/32nd of the genome.
Integration of genome or exome sequencing with link-
age analysis is also a powerful approach that can narrow
the list of candidate genes. This approach has been suc-
cessfully used to identify mutations associated with meta-
chondromatosis (Sobreira et al. 2010), osteogenesis
imperfect (Volodarsky et al. 2013; Cho et al. 2012),
Chartcot-Marie-Tooth disease (Kennerson et al. 2013),
spinocerebellar ataxia (Lee et al. 2012), opsismodysplasia
(Below et al. 2013), distal arthrogryposis (McMillin et al.
2013), craniocervical dystonia (Charlesworth et al. 2012),
dyskinesia and facial myokymia (Chen et al. 2012), tho-
racic aortic aneurysm syndrome (Boileau et al. 2012),
distal hereditary motor neuropathy (Beetz et al. 2012),
spinal muscular atrophy (Zhou et al. 2012), familial pity-
riasis rubra pilaris (Fuchs-Telem et al. 2012) and many
others (Ku et al. 2011). In many cases, this approach
enables gene mapping in only a single affected individual
and can substantially narrow the list of candidate mutations
generated by WES/WGS. For instance, in a study of
metachondromatosis, the inclusion of linkage data reduced
the number of candidate genes with disruptive mutations
from 109 across the whole genome to only one found in a
linkage region (Sobreira et al. 2010).
These tremendous technological breakthroughs raise the
tantalizing possibility that in the near future we may dis-
cover the molecular etiology of most, or even all, Men-
delian diseases. Achieving this remarkable goal will
require world-wide collaboration bringing together clini-
cians caring for patients with rare Mendelian diseases and
experts in genome technologies as well as computational
biology. Consortia such as the Finding of Rare Disease
Genes (FORGE) in Canada, the International Rare Dis-
eases Research Consortium in Europe and the Centers for
Mendelian Genomics by the National Institutes of Health
in the United States (Bamshad et al. 2012) should have a
major impact on applying genomic technologies to unrav-
eling Mendelian disorders.
Unexpected phenotypes as a clue to modifier
or suppressor mutations
The widespread availability of sequence data also permits
identification of unexpected splits between genotype and
phenotype that may suggest the presence of a suppressor or
modifier mutation. Examples of this include individuals
Fig. 2 Theoretical example of
filtering steps used to limit
number of variants identified by
exome sequencing. The three
examples indicate two affected
individuals who are related to
different degrees. Comparing
the exomes of siblings, 1st
cousins or 2nd cousins will limit
candidate variants to the
roughly 1/2th, 1/8th or 1/32nd
of the genome, respectively, that
is shared by two such
individuals. Additional discrete
filtering and bioinformatics
steps can further reduce the
number of candidate variants.
Examples assume that all but
2 % of variants will be
identified in public databases
such as dbSNP and 1000
Genomes Project and that
approximately 20 % of novel
variants will be predicted to be
deleterious to the function of the
encoded protein
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with pathogenic mutations in the LDL receptor gene but
normal cholesterol levels (Hobbs et al. 1989), or patients
with an expanded CAG repeat in the Huntington disease
gene who have not manifest disease by the 95th percentile
of age expected for that CAG repeat length, or conversely
those that have manifest disease prior to the 5th percentile
of age expected (Langbehn et al. 2004; Brinkman et al.
1997). Other examples include individuals homozygous for
the ApoE e4 allele who remain free of Alzheimer’s late
into life, or individuals homozygous for null alpha-1 anti-
trypsin alleles (i.e., ZZ genotype) who do not develop
obstructive airways disease. All of these examples point to
the presence of a mutation in another gene that masks the
expected phenotype.
We recently described two families with mutations in
the SCARB1 gene that encodes the HDL receptor, SR-BI
(Brunham et al. 2011) and was recently reported to be a
cause of high HDL-C levels in humans (Vergeer et al.
2011). While most individuals who carried the SCARB1
mutations had elevated HDL cholesterol (HDL-C) ([95th
percentile for age and gender), one mutation-carrier was
observed to have unexpectedly low HDL-C (15th percen-
tile). Sequencing of candidate low HDL-C genes in this
individual led to the identification of novel mutation in
ABCA1, V2091I, that segregated with low HDL-C and may
be the cause of this individual’s low HDL-C thereby
explaining the unexpected phenotype in that patient.
As more genome and exome data become available for a
larger and larger number of individuals, we will have
increasing opportunity to identify unexpected phenotypes
in the presence of a given genotype. The importance of
these observations is in pointing to the presence of poten-
tial suppressor genes that in many instances may represent
novel therapeutic targets. For instance, individuals with
familial hypercholesterolemia (FH)-causing mutations but
normal levels of LDL-C suggest the presence of a mech-
anism for lowering LDL-C that is independent of the LDL
receptor and would, therefore, be effective in individuals
with FH, one of the most common causes of inherited high
cholesterol. The identification of such suppressor mutations
may lead to novel approaches to modify the course of ill-
ness by identifying therapeutic targets that have already
been validated in relevant human disease models.
Disease genes for common diseases
In contrast to the remarkable success achieved in the
identification of genes for Mendelian diseases, common
diseases have proved much more difficult to unravel.
Linkage studies for complex disease proved extremely
difficult due to a lack of sufficient genomic resolution to
identify disease-associated loci using microsatellite
markers and inadequate power to detect an association,
largely due to the significant locus heterogeneity that
characterizes common disease (John et al. 2004; Altmuller
et al. 2001; Xiong and Guo 1998). An alternative approach
was therefore developed, genetic association studies, in
which the frequency of common DNA polymorphisms is
compared in unrelated cases versus controls. Association
studies provide much greater power to detect variants
associated with common disease than does linkage analy-
sis, particularly when the risk conferred by the gene is
modest (Risch and Merikangas 1996). The DNA marker
studied need not be causal for the disease in question;
because of patterns of linkage disequilibrium (LD) in the
genome, nearby DNA markers tend to be inherited toge-
ther. Indeed, the discovery that recombination tends to
occur at specific ‘‘hot spots’’ (McVean et al. 2004; Daly
et al. 2001) suggested that a single ‘‘tag’’ single nucleotide
polymorphism (SNP) could capture most of the common
DNA variation in a particular genomic region (Johnson
et al. 2001).
Initial association studies were limited to examining
candidate genes and therefore were not suited to the
identification of novel genetic risk loci (Tabor et al. 2002).
Multiple technical and conceptual advances changed this,
including the development of high-throughput genotyping
technologies capable of genotyping thousands of SNPs in
large numbers of individuals, large catalogues of SNPs
(Sachidanandam et al. 2001), knowledge of patterns of LD
in the genome (International HapMap Consortium 2003)
and analytic frameworks to analyze enormous datasets. By
2006, genome-wide association studies (GWAS) became a
reality (Hirschhorn and Daly 2005). GWAS involves
genotyping high-density panels of polymorphisms in sev-
eral thousand cases and controls to identify common
variants ([1 % allele frequency) that are hypothesized to
underlie some portion of the heritability of common dis-
eases. The basis for these studies is the common disease–
common variant hypothesis which posits that genetic risk
for common diseases will be due at least in part to a small
number of disease-predisposing alleles per locus that exist
at high frequency (Lander 1996; Chakravarti 1999).
More than 1,000 GWAS have now been reported with
evidence of association of thousands of SNPs for dozens of
common conditions (Hindorff et al. 2012) and has led to
substantial advances in our understanding of the role of
common variation in common disease (Altshuler et al.
2008). In general, GWAS has been successful in identify-
ing numerous variants that are associated with common
disease at high levels of statistical significance; however,
most of these alleles confer only small effects sizes (Odds
ratios\1.5). As such, GWAS has largely not succeeded in
identifying disease genes with large effects, raising the
concept of the ‘‘missing heritability’’ of common disease
Hum Genet (2013) 132:603–617 607
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(Manolio et al. 2009). Rare variants or structural variants
not represented on GWAS genotyping panels may be a
source of this missing heritability (Manolio et al. 2009).
Alternatively, estimates of heritability may themselves be
inaccurate, for instance, due to the effect of gene–gene
interactions which are generally not incorporated into
heritability estimates and would have the effect of
increasing the heritability apparently left to account for
(Zuk et al. 2012).
How will we move forward to uncover the remaining
heritability of these common conditions? One exciting
approach is the use of genotyping and next-generation
sequencing technologies to identify rare and private vari-
ants. The alternative to the common disease–common
variant hypothesis is that most variants underlying disease
in humans will be individually rare because any variant
with a major effect on fitness will tend to be removed from
the population by the actions of natural selection, thus
keeping the frequency of such variants very low. Indeed,
rare variants are 4 times more likely to be functional (based
on bioinformatics predictions) than are more common
variants (minor allele frequency greater than 0.5 %)
(Tennessen et al. 2012). Most of the variation in the human
genome consist of common variants that arose prior to the
migration of modern humans out of Africa and are shared
between continental populations—these are the variants
represented in HapMap (International HapMap Consortium
2003) that form the basis for GWAS. However, the vast
majority of the coding, polymorphic alleles in humans are
individually rare and represent evolutionarily recent
mutations that have occurred with the rapid population
expansion over the past 10,000 years (Tennessen et al.
2012). If common human diseases are characterized
genetically by marked allelic and locus heterogeneity, as
has been postulated (McClellan and King 2010), then new
methods will be required to identify the rare alleles that
contribute to human disease.
A study of sick sinus syndrome (SSS) in the Icelandic
population is illustrative of how these rare variants can be
identified. These investigators initially performed GWAS
in a population of *800 cases and nearly 40,000 popula-
tion-based controls to define a region on chromosome
14q11 that contained 3 SNPs associated with SSS at gen-
ome-wide levels of significance. Subsequent WGS in a
selection of 87 individuals identified 11 million variants
that were then imputed into the GWAS cases and controls
using long-range haplotype phasing (Kong et al. 2008).
This approach identified a rare coding variant (minor allele
frequency 0.38 % in Icelandic population) in the MYH6
gene, located at the 14q11 locus, that was associated with
SSS with an Odds ratio of 12.5 and p value of 1.5 9 10-29
(Holm et al. 2011). This association was further validated
by direct genotyping in an additional set of SSS cases and
controls. This study provides compelling evidence of a rare
variant with large effect size that impacts a complex trait
and provides impetus for efforts to identify such variants
for common diseases broadly. This study also suggests that
combining GWAS, WGS and imputation in a population
isolate serves as one method by which this class of variant
can be identified.
Imputation of rare variants identified by WGS into
patients who have been genotyped for GWAS panels pro-
vides a cost-effective method for performing association
studies of a large number of rare, potentially functional
variants. This approach was used, also in the Icelandic
population, to identify a missense substitution (R47H) in
the TREM2 gene, with an allele frequency of 0.12–0.63 %
in the various populations studied, that confers a threefold
increased risk of Alzheimer’s disease (Jonsson et al. 2012).
The same TREM2 variant was simultaneously identified by
a candidate gene sequencing approach and was found to
occur significantly more frequently in individuals with
Alzheimer’s compared to controls (Guerreiro et al. 2012).
The imputation of rare variants provides one attractive
means to extend the unbiased nature of GWAS to low-
frequency variants selected for potential functionality.
Similarly, ‘‘exome-chip’’ approaches will soon enable
direct genotyping of several hundred thousand putatively
functional low-frequency coding variants identified by
WGS or WES (Kathiresan and Srivastava 2012).
Ultimately, the most comprehensive approach for
searching for rare variants that influence common disease
will be WGS or WES of large numbers of cases and
controls to identify variants associated with these phe-
notypes. Though this strategy remains both technically
and economically prohibitive at present, it will no doubt
be deployed in the near future. A key consideration of
such studies would be the statistical power to detect an
association. Because power decreases as a function of
allele frequency, very large sample sizes will likely be
necessary to identify disease-association of rare variants.
With several hundred cases and controls, very few genes
have adequate power to identify a rare variant that confers
an Odds ratio of 5 or more (Tennessen et al. 2012). For
smaller effect sizes, such as 1.5, several thousand cases
and controls will be required (Raychaudhuri 2011).
Accepted levels of statistical significance that take into
account the burden of multiple testing for rare variants
across the genome or exome need to be established and
will be more stringent than levels used in GWAS
reflecting the far greater number of rare than common
variants in the genome; a p value of 10-11 has been
proposed (Raychaudhuri 2011). Issues of incomplete
penetrance, genetic heterogeneity, and gene–gene and
gene-environment interactions will be additional compli-
cations requiring close attention.
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Using population extremes to identify disease genes
An additional strategy to identify rare variants that confer
disease risk involves studying individuals representing the
ends of a quantitative phenotype, a strategy known as
‘‘sequencing the extremes’’ (Fig. 3). The prototypical study
to establish this approach involved sequencing 3 candidate
genes for low levels of HDL-C, ABCA1, APOA1 and
LCAT, in individuals with the lowest and highest 5 % of
HDL-C levels in a population (Cohen et al. 2004). The
number of non-synonymous sequence variants in these
genes that were unique to either the low or high HDL-C
groups was compared and revealed a statistically signifi-
cant excess of rare mutations among individuals with low
HDL-C (20 versus 3 in the low versus high HDL-C
groups). Most of these mutations were in the ABCA1 gene
(Cohen et al. 2004).
This method has subsequently been used to provide
evidence that rare variants in specific genes influence levels
of LDL-C (Cohen et al. 2005) and intestinal sterol
absorption (Cohen et al. 2006; Fahmi et al. 2008), tri-
glycerides (Hobbs et al. 1989; Romeo et al. 2007), body
mass (Ahituv et al. 2007) and high levels of HDL-C
(Brunham et al. 2011; Tietjen et al. 2012). A re-sequencing
study of four genes implicated by GWAS to be associated
with hypertriglyceridemia demonstrated that these same
genes harbor an excess of rare variants, with 28.1 % of
hypertriglyceridemic individuals carrying a rare variant in
one of these genes compared to 15.3 % of individuals with
normal triglyceride levels (Johansen et al. 2010). Impor-
tantly, this demonstrates that some portion of the vari-
ability of common disease is likely due to rare variants in
the same genes in which common variation has been
associated with these traits.
Sequencing the extremes has emerged as a powerful tool
to provide evidence for the role of rare mutations in spe-
cific genes impacting complex traits. However, a limitation
of this approach has been that it is restricted to candidate
genes. For instance, in the study of low levels of HDL-C
described above, the ABCA1, APOA1 and LCAT genes
were chosen because mutations in each of these genes are
known to cause rare, recessive Mendelian conditions of
low HDL-C. To identify novel disease genes, this approach
would need to be extended to perform WGS or WES in the
population extremes of a trait.
Indeed, such a strategy has recently been reported to
discover a gene that impacts Pseudomonas infection in
individuals with cystic fibrosis (Emond et al. 2012). Most
patients with CF become colonized with Pseudomonas
early in life with a median of 1 year (Li et al. 2005), but
substantial variability exists in this phenotype. Emond et al.
(2012) identified two groups of patients representing the
extremes of Pseudomonas colonization: those who became
chronically infected prior to the 10th percentile age of
onset and those who remained culture negative beyond
14 years of age. Exome sequencing of these individuals
identified a single gene, DCTN4, that showed statistically
significant evidence of association with time to Pseudo-
monas infection after correcting for multiple testing. This
study suggests that the extreme phenotype approach can be
successfully combined with exome sequencing to identify
novel genes involved in complex traits. More studies are
clearly needed to determine if this will prove to be a suc-
cessful approach in general and new analytic methods are
required to assess the statistical significance of rare variants
identified through such approaches.
De Novo mutations and copy number variants
in human disease
The availability of WGS and WES also affords the
opportunity to delineate DNA variants that are present in
the genome or exome of an offspring but absent in that
individual’s parents. This trio-sequencing approach not
only enables accurate determination of the mutation rate
but also importantly allows for precise identification of de
novo mutations at single nucleotide resolution (Veltman
Fig. 3 Sequencing the extremes to identify rare variants involved in
common disease. The individuals from the high and low ends of the
population distribution of a trait are chosen for study. Either candidate
genes or whole exomes or genomes are sequenced and the number of
rare variants in a given gene is compared between the high and low
groups. An excess of rare sequence variants in a given gene in the
high versus low (or vice versa) group provides evidence for a role of
that gene in the phenotype under study. See text for examples of
where this has been used
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and Brunner 2012). De novo mutations are, in a sense, the
most extreme form of rare mutations, in that they may be
private and have not been subject to selective pressure in
previous generations. These variants are therefore prime
suspects for playing a role in human disease.
Several recent studies have examined the contribution of
de novo mutations to common disease. Four recent studies
reported exome sequencing of ‘trios’ (affected child and
parents) or ‘quads’ (affected child, unaffected sibling and
parents) in families with autism spectrum disorder (ASD)
(Neale et al. 2012; O’Roak et al. 2012; Sanders et al. 2012;
Iossifov et al. 2012). These studies found a small increase
in de novo mutations in ASD cases compared to unaffected
controls that tended to occur in genes that are biologically
related to each other or to previously known ASD genes.
These mutations were predominantly paternal in origin,
and the number of mutations increased with increasing
paternal age, consistent with the known increased risk of
ASD to children of older fathers.
While the ability to accurately detect such mutations
opens the door to many exciting lines of discovery that may
account for some of the missing heritability of common
disease, these studies also highlight many challenges. For
instance, how do we interpret the biological significance of
these mutations and link them with disease? In particular,
how do we distinguish a single de novo mutation, even an
apparently deleterious one, from the substantial background
of mutational events that these studies have demonstrated?
These studies also highlight the extreme genetic heteroge-
neity of these disorders. For example, of the more than 120
genes implicated in the studies of autism, only six genes had
disruptive mutations in more than one individual (Muers
2012). While this may suggest that ASD represents hundreds
of genetically distinct entities, it remains unclear to what
extent this sub-classification will yield meaningful clinical
insight.
One class of genetic variation with a large contribution
from de novo events is structural variation that affects the
number of copies of a particular chromosomal region and can
thereby impact phenotypes via a gene-dosage effect of the
implicated gene or genes. Our understanding of the diversity
of copy number variants (CNVs) has advanced dramatically
in recent years and we now know that CNVs are remarkably
common in the genomes of normal individuals (Sebat et al.
2004; Iafrate et al. 2004). While some CNVs are polymor-
phic in human populations, most are rare or private. Most
CNVs are thought to arise due to non-allelic homologous
recombination between highly identical regions of the gen-
ome (Girirajan et al. 2011). CNVs affect an order of mag-
nitude more base pairs in the genome than do SNPs (Lupski
2007), and more than one-third of all human genes may be
partially or totally in the region of a CNV (Gonzaga-Jauregui
et al. 2012). The Database of Genomic Variants currently
listed more than 15,000 CNV loci in the human genome (The
Database of Genomic Variants 2013).
CNVs have long been associated with ‘genomic disor-
ders’—rare highly penetrant syndromes typically associ-
ated with neurodevelopmental delay (Girirajan et al. 2011).
Rare CNVs have also been documented to play an
important role in psychiatric and behavioral conditions
such as schizophrenia and ASD (Xu et al. 2008; Walsh
et al. 2008; Sebat et al. 2007). More recently, a CNV at 17p
was shown to influence obesity traits in mice, with deletion
of this region leading to obesity and metabolic syndrome,
and duplication leading to protection from obesity (Lacaria
et al. 2012). CNVs have also been reported to play a role in
congenital heart disease (Soemedi et al. 2012; Hitz et al.
2012), epilepsy (Helbig et al. 2009) and many other con-
ditions (Zhang et al. 2009; Stankiewicz and Lupski 2010;
Girirajan et al. 2011).
Comprehensive detection of CNVs in the human gen-
ome remains a challenge but recent technological advances
have accelerated our ability to do so. In particular, array
comparative genome hybridization and paired-end map-
ping, in which the presence of a CNV is suggested by a size
difference between the fragment length and the corre-
sponding region of the reference sequence (Korbel et al.
2007). Notably, these methods allow for accurate detection
of smaller CNVs with more precise resolution of break-
points. Widespread application of these techniques to an
expanding list of common diseases should provide further
insight into the role of CNVs in common genetic diseases.
What constitutes proof that a mutation causes
a disease?
How do we prove that a mutation in a gene is causative of
disease? Linkage analysis can provide evidence of DNA
variants in a gene that segregate with disease in a family.
Finding mutations in the same gene in unrelated families
provide additional evidence of causality. For highly char-
acteristic rare phenotypes that segregate in a family, the
accepted standard is replication across three independent
families. For variants identified in extremely rare or private
phenotypes, the burden of proof is less well defined and new
analytic methods are required. This underscores an impor-
tant principle relevant to both traditional and contemporary
gene mapping. Namely, that finding different, rare, patho-
genic mutations in the same gene or in the same biological
pathway, in unrelated individuals with the same phenotype
provides important support for that gene being involved in a
given biological process (McClellan and King 2010).
Bioinformatics algorithms such as Polyphen (Adzhubei
et al. 2010), SIFT (Kumar et al. 2009), SNAP (Johnson et al.
2008) or PANTHER (Mi et al. 2010) are frequently used as a
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first approximation for determining if a given DNA or
amino-acid sequence variant is likely to impair the function
of the encoded protein. Most of these programs rely on some
combination of conservation of the site in question in related
proteins within and across species as well as knowledge of
structure of the protein. Functional data for a limited number
of genes suggest that these methods have reasonable accu-
racy for the prediction of deleterious effects on specific
proteins (Ng and Henikoff 2006). For example, PANTHER
correctly identified as deleterious or benign *95 % of rare
variants in the ABCA1 gene (Brunham et al. 2005). However,
none of these methods are perfectly sensitive or specific.
Indeed, in the exome sequencing study that identified the
molecular cause of Miller syndrome, the use of Polyphen as a
filter for functional variants would have excluded the
mutation in DHODH, ultimately found to be causative of that
disease (Ng et al. 2010). Moreover, agreement among the
various methods are poor: in a deeply sequenced set of ex-
ome data, about half of all detected SNPs were predicted to
be functional by at least one of seven different bioinformatics
programs, but the various programs were in full agreement
on only 1 % of variants (Tennessen et al. 2012).
Functional studies are, therefore, crucial to establish
which DNA variants truly impact protein function and are
causal in disease. This remains a major rate-limiting step,
because, for most gene-products, a readily availably func-
tional assay does not exist. For many genes, we simply do
not know enough about the function of the gene-product
and therefore lack methods for testing the consequence of
sequence variation, especially in high-throughput fashion.
Full functional annotation of all human genes remains a
lofty and distant goal.
In GWAS, proof generally takes the form of a level of
statistical significance. In particular, a p value threshold of
5 9 10-8 is felt to reflect the nominal significance threshold
of a finding being due to chance 1 in 20 times corrected for
the approximately 1 million independent tests incurred in a
genome-wide scan (Pe’er et al. 2008). However, it is
important to note that this provides evidence only of asso-
ciation and not of causation. Despite these high levels of
statistical stringency, most variants identified by GWAS are
in non-coding regions of the genome and the causal variant is
often unknown. This may be explained by linkage disequi-
librium between the associated variant and a true functional
variant, or by a regulatory effect of a non-coding variant.
Differentiating between these possibilities can be extremely
challenging.
For example, a locus at 1p13 was known to be strongly
associated with LDL cholesterol in a meta-analysis of
[100,000 individuals (Teslovich et al. 2010). Fine-mapping
of this region identified 6 SNPs that showed the greatest
degree of association in the genomic region between the
genes CELSR2 and PSRC1 (Musunuru et al. 2010) but the
causative variant was not obvious. Sequential testing of these
variants identified a single SNP that resulted in increased
gene expression by creating a transcription factor binding
site for SORT1, a gene shown to regulate hepatic VLDL
secretion.
A second example involves variants in a gene desert at
chromosome region 9p21 associated with coronary artery
disease (McPherson et al. 2007). Through a series of
computational and experimental approaches using immor-
talized cell lines, Harismendy et al. 2011 demonstrated that
a single SNP in this region interrupts a binding site for
STAT1, a transcription factor implicated in inflammatory
responses, and that this locus participates in a long-range
physical interaction with the CDKN2A/B locus. These two
examples highlight how challenging it is to move from
genetic association to mechanistic insight, but provide
important models for how this may be achieved.
Conclusions
The past decade has witnessed tremendous progress in the
identification of the molecular bases of human disease.
Indeed, for Mendelian disorders, it is conceivable that in
the future we may possess a complete catalogue of the
genetic basis for each of these conditions. Common dis-
eases continue to be much more challenging to address, but
recent advances in sequencing and genotyping methods are
yielding exciting results. Next-generation sequencing has
dramatically altered our ability to identify human disease
genes, but many challenges remain. In particular, our
ability to ascribe functional significance to a given DNA
variant remains limited. Ultimately, the identification of the
molecular causes of disease will continue to illuminate the
pathophysiology of both common and rare conditions and
offer opportunities for improvements in the diagnosis,
treatment and prevention of disease.
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